

# Doris M Ponce

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6903937/publications.pdf>

Version: 2024-02-01

71  
papers

3,660  
citations

279798

23  
h-index

138484

58  
g-index

71  
all docs

71  
docs citations

71  
times ranked

4454  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. <i>Blood Advances</i> , 2022, 6, 1525-1535.	5.2	17
2	Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 55.e1-55.e5.	1.2	5
3	CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis. <i>Bone Marrow Transplantation</i> , 2022, 57, 1101-1107.	2.4	3
4	Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogeneic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 1095-1100.	2.4	4
5	MAIT and V $\alpha$ 2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	19
6	Racial disparities in access to alternative donor allografts persist in the era of "donors for all". <i>Blood Advances</i> , 2022, 6, 5625-5629.	5.2	12
7	Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin. <i>Leukemia</i> , 2021, 35, 850-862.	7.2	8
8	Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 289-292.	2.4	4
9	Combining the disease risk index and hematopoietic cell transplant comorbidity index provides a comprehensive prognostic model for CD34 <sup>+</sup> -selected allogeneic transplantation. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, .	0.9	0
10	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2177-2183.	1.3	2
11	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6.	1.2	11
12	Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 920.e1-920.e9.	1.2	1
13	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1878-1887.	1.6	14
14	Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. <i>Blood Advances</i> , 2021, 5, 2879-2889.	5.2	16
15	Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 540-544.	1.2	11
16	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 3394-3401.	1.3	17
17	Real-time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology. <i>Transplantation and Cellular Therapy</i> , 2021, , .	1.2	3
18	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 771.e1-771.e10.	1.2	17

#	ARTICLE	IF	CITATIONS
19	Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 852.e1-852.e9.	1.2	0
20	MAIT and V $\alpha$ 2 Unconventional T Cells Predict Favorable Outcome after Allogeneic HCT and Are Supported By a Diverse Intestinal Microbiome. <i>Blood</i> , 2021, 138, 331-331.	1.4	2
21	Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 1814-1814.	1.4	0
22	Haematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of <i>Candida parapsilosis</i> complex species. <i>Nature Microbiology</i> , 2021, 6, 1505-1515.	13.3	35
23	Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All". <i>Blood</i> , 2021, 138, 423-423.	1.4	1
24	Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3915-3915.	1.4	4
25	Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft. <i>Bone Marrow Transplantation</i> , 2020, 55, 1632-1634.	2.4	0
26	Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 323-332.	2.0	19
27	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. <i>Blood Advances</i> , 2020, 4, 6064-6076.	5.2	29
28	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834.	27.0	435
29	Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. <i>Journal of Palliative Medicine</i> , 2020, 23, 1653-1657.	1.1	1
30	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 733-747.	8.2	161
31	The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. <i>Blood</i> , 2020, 136, 130-136.	1.4	97
32	Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
33	Secondary Graft-Versus-Host Disease (GVHD) Prophylaxis with Oral Proteasome Inhibitor Ixazomib Is Associated with Low Incidence of Recurrent, Late Acute and Chronic GVHD and Facilitated Calcineurin Inhibitor Taper within the First Year Post Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 41-42.	1.4	0
34	Inpatient Management of Mucocutaneous GVHD. <i>Current Dermatology Reports</i> , 2019, 8, 258-278.	2.1	6
35	Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. <i>Blood Advances</i> , 2019, 3, 939-944.	5.2	56
36	Establishing a standardized system for review and adjudication of chronic graft-versus-host disease data in accordance with the National Institutes Consensus criteria. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e62.	0.9	6

#	ARTICLE	IF	CITATIONS
37	Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1079-1087.	2.0	20
38	Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	258
39	Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 608-608.	1.4	9
40	The Prognostic Calculator Easix Predicts Acute Gvhd, Non-Relapse Mortality and Overall Survival in Adult Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT. <i>Blood</i> , 2018, 132, 2069-2069.	1.4	4
41	Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 965-970.	2.0	31
42	Ex Vivo CD34+â€Selected T Cellâ€Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 452-458.	2.0	35
43	Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 + Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 67-74.	2.0	24
44	Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 1650-1659.	1.6	252
45	Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2017, 130, 747-747.	1.4	6
46	Analysis of Cyclosporine A Levels Supports New Dosing Guidelines in Adult Double-Unit Cord Blood Transplant Recipients to Optimize Immunosuppression Early Post-Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1533-1534.	2.0	9
47	InÂVivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2173-2179.	2.0	21
48	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. <i>Blood</i> , 2015, 125, 199-205.	1.4	109
49	CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2106-2114.	2.0	49
50	Intestinal <i>Blautia</i> Is Associated with Reduced Death from Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1373-1383.	2.0	619
51	Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 920-925.	2.0	33
52	Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 1799-1805.	1.3	30
53	Association between Nondominant Unit Total Nucleated Cell Dose and Engraftment in Myeloablative Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1981-1984.	2.0	9
54	Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2160-2166.	2.0	31

#	ARTICLE	IF	CITATIONS
55	High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1985-1993.	2.0	40
56	Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 663-670.	1.3	18
57	Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 787-793.	2.0	43
58	Sustained Donor Engraftment in Recipients of Double-Unit Cord Blood Transplantation Is Possible Despite Donor-Specific Human Leukoctye Antigen Antibodies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 735-739.	2.0	21
59	Higher Mycophenolic Acid (MPA) Trough Levels Result in Lower Day 100 Severe Acute Graft-Versus-Host Disease (aGVHD) without Increased Toxicity in Double-Unit Cord Blood Transplantation (CBT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S52-S53.	2.0	2
60	Double-Unit Cord Blood (CB) Transplantation Combined with Haplo-Identical CD34+ Cells Results in 100% CB Engraftment with Enhanced Myeloid Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S138-S139.	2.0	3
61	No Wash-Albumin-Dextran Dilution for Double-Unit Cord Blood Transplantation is Safe with High Rates of Sustained Donor Engraftment. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 490-494.	2.0	18
62	The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 124, 1174-1182.	1.4	711
63	Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. <i>Blood</i> , 2014, 124, 2905-2912.	1.4	74
64	Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect. <i>Blood</i> , 2014, 124, 2459-2459.	1.4	1
65	A Novel Reduced-Intensity Conditioning Regimen Induces a High Incidence of Sustained Donor-Derived Neutrophil and Platelet Engraftment after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 799-803.	2.0	63
66	Higher Mycophenolic Acid (MPA) Trough Levels Result In Lower Day 100 Severe Acute GVHD Without Increased Toxicity In Double-Unit Cord Blood Transplantation (CBT) Recipients. <i>Blood</i> , 2013, 122, 3297-3297.	1.4	1
67	The Use of Back-up Units to Enhance the Safety of Unrelated Donor Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 648-651.	2.0	17
68	Poor Graft Function in Recipients of T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplants (HSCT) Is Mostly Related to Viral Infections and Anti-Viral Therapy. <i>Blood</i> , 2012, 120, 3147-3147.	1.4	5
69	Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience. <i>Blood</i> , 2012, 120, 1996-1996.	1.4	0
70	Reduced Late Mortality Risk Contributes to Similar Survival after Double-Unit Cord Blood Transplantation Compared with Related and Unrelated Donor Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1316-1326.	2.0	72
71	Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies. <i>Blood</i> , 2009, 114, 2296-2296.	1.4	6